FDA Grants Fast-Track Designation to ELND005

The FDA awarded fast-track designation to Elan’s ELND005. The drug, which is still in multiple trials, is meant to reduce agitation and aggression that are often part of Alzheimer’s disease.
Yahoo! Finance